Clinical Trial Update | Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial – Journal of Clinical Oncology

Original Study: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine

News Release: Trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer – Yale University

Commentary: Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC – The ASCO Post